LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
11 hedge funds and large institutions have $3.34M invested in LakeShore Biopharma in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
0.01% less ownership
Funds ownership: 0.29% → 0.27% (-0.01%)
12% less capital invested
Capital invested by funds: $3.79M → $3.34M (-$459K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$202K |
| 2 |
OCM
Ovata Capital Management
Hong Kong
|
+$123K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$33.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$385K |
| 2 |
O
OrbiMed
New York
|
-$106K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$42K |
| 4 |
PAM
Pinpoint Asset Management
Hong Kong
|
-$3.58K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$359 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $910K | -$106K | -13,015 | -8% |
|
2
Fidelity Investments
Boston,
Massachusetts
| $755K | – | – | – |
|
|
HA
3
HHLR Advisors
Grand Cayman,
Cayman Islands
| $487K | – | – | – |
|
|
4
Fidelity International
Hamilton,
Bermuda
| $475K | -$385K | -47,134 | -39% |
|
|
5
Bank of Montreal
Toronto,
Ontario, Canada
| $296K | -$42K | -5,142 | -15% |
|
|
SCM
6
Superstring Capital Management
New York
| $200K | – | – | – |
|
|
7
Barclays
London,
United Kingdom
| $160K | +$202K | +24,758 | New |
|
|
8
Citadel Advisors
Miami,
Florida
| $26.4K | +$33.3K | +4,068 | New |
|
|
OCM
9
Ovata Capital Management
Hong Kong
| $10.2K | +$123K | +15,000 | New |
|
10
Geode Capital Management
Boston,
Massachusetts
| $8.82K | – | – | – |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $7.56K | +$9.54K | +1,167 | New |
|
|
PAM
12
Pinpoint Asset Management
Hong Kong
| – | -$3.58K | -5,000 | Closed |
|
|
WAM
13
Wolverine Asset Management
Chicago,
Illinois
| – | -$359 | -50 | Closed |
|
LSB Hedge Fund Activity: Q2 2024 in Review
11 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q2 2024, worth a combined $3.34M — down 12% from $3.79M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LSB positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 3 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $202K. The largest seller was Fidelity International, cutting an estimated $385K.
- 11 institutional investors held LakeShore Biopharma (LSB) as of Q2 2024, up from 9 in Q1 2024.
- Funds reported $3.34M of LakeShore Biopharma stock for Q2 2024, down 12% quarter-over-quarter.
- 4 funds opened new LakeShore Biopharma positions in Q2 2024 and 2 closed out, a net change of +2 holders.
- The largest LakeShore Biopharma buyer in Q2 2024 was Barclays, an estimated $202K added.
- The largest LakeShore Biopharma seller in Q2 2024 was Fidelity International, an estimated $385K sold.
Based on aggregated 13F filings for Q2 2024.